P1123: TEMPO: A PHASE 2, RANDOMIZED, OPEN-LABEL, 2-ARM STUDY COMPARING TWO INTERMITTENT DOSING SCHEDULES OF DUVELISIB IN SUBJECTS WITH INDOLENT NON-HODGKIN LYMPHOMA (INHL). (23rd June 2022) - Vorobyev, V.; Yoon, D. H.; Kaźmierczak, M.; Grosicki, S.; Tarella, C.; Genua, A.; Kim, J. S.; Cohan, D.; Daugherty, M.; Flinn, I. W.; Zinzani, P. L.; Gordon, L. I.